Cuiping Lin Xuan Li Yu Qiu Zheng Chen Jianping Liu
10.3389/fpubh.2022.885001
Front Public Health
2022 Aug 5;10:885001.
pd-1 inhibitors camrelizumab diabetes immune checkpoint inhibitor insulin
CC BY
https://pubmed.ncbi.nlm.nih.gov/35991054/
Diabetes Mellitus, Type 1 / chemically induced Diabetes Mellitus, Type 1 / diagnosis Nivolumab / adverse effects
Diabetes Mellitus, Type 1 / chemically induced Diabetes Mellitus, Type 1 / diagnosis Nivolumab / adverse effects Case Reports Systematic Review Aged Coma / chemically induced Female Humans Immune Checkpoint Inhibitors Immune Checkpoint Inhibitors Nivolumab
PMC9389003
35991054
PD-1 inhibitor-associated type 1 diabetes: A case report and systematic review
2022